Patents by Inventor Holger Wesche

Holger Wesche has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220267462
    Abstract: Provided herein are EpCAM binding proteins, pharmaceutical compositions comprising such proteins or fragments thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such EpCAM binding proteins. Also disclosed are methods of using the disclosed EpCAM binding proteins in the prevention, and/or treatment diseases, conditions and disorders.
    Type: Application
    Filed: May 14, 2020
    Publication date: August 25, 2022
    Inventors: Holger WESCHE, Richard J. AUSTIN, Shuoyen Jack LIN, Bryan LEMON, Kevin WRIGHT, Sony ROCHA, Kathryn KWANT
  • Publication number: 20220112297
    Abstract: Provided herein are B cell maturation agent (BCMA) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to BCMA. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such BCMA targeting trispecific proteins. Also disclosed are methods of using the disclosed BCMA targeting trispecific proteins in the prevention, and/or treatment diseases, conditions and disorders.
    Type: Application
    Filed: September 14, 2021
    Publication date: April 14, 2022
    Inventors: Holger WESCHE, Bryan D. LEMON, Richard J. AUSTIN
  • Publication number: 20220098311
    Abstract: Provided herein are FLT3 binding proteins, pharmaceutical compositions comprising such proteins or fragments thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such FLT3 binding proteins. Also disclosed are methods of using the disclosed FLT3 binding proteins in the prevention, and/or treatment of diseases, conditions and disorders.
    Type: Application
    Filed: October 12, 2021
    Publication date: March 31, 2022
    Inventors: Holger WESCHE, Richard J. AUSTIN
  • Publication number: 20220054544
    Abstract: Disclosed herein are conditionally active receptors which comprise a target antigen binding domain and a binding moiety. Each binding moiety comprises non-CDR loops for masking the binding of a target antigen binding domain to its target. The receptors are activated upon cleavage of the cleavable linkers. Pharmaceutical compositions comprising cells comprising the conditionally active receptors disclosed herein and methods of using such formulations are further provided.
    Type: Application
    Filed: May 14, 2019
    Publication date: February 24, 2022
    Inventors: Shuoyen Jack LIN, Richard J. AUSTIN, Bryan D. LEMON, Kevin WRIGHT, Holger WESCHE
  • Publication number: 20220017626
    Abstract: Provided herein are EGFR binding proteins and EGFR targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to EGFR. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such EGFR binding proteins, EGFR targeting trispecific proteins. Also disclosed are methods of using the disclosed EGFR binding proteins, EGFR targeting trispecific proteins in the prevention, and/or treatment diseases, conditions and disorders.
    Type: Application
    Filed: September 20, 2019
    Publication date: January 20, 2022
    Inventors: Holger WESCHE, Richard J. AUSTIN
  • Patent number: 11180563
    Abstract: Provided herein are FLT3 binding proteins, pharmaceutical compositions comprising such proteins or fragments thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such FLT3 binding proteins. Also disclosed are methods of using the disclosed FLT3 binding proteins in the prevention, and/or treatment of diseases, conditions and disorders.
    Type: Grant
    Filed: February 19, 2021
    Date of Patent: November 23, 2021
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Holger Wesche, Richard J. Austin
  • Publication number: 20210355219
    Abstract: Disclosed herein are conditionally active multivalent target-binding proteins which comprise two binding moieties, two linkers, two target antigen binding domains, and a constant domain. Each binding moiety comprises non-CDR loops for masking the binding of a target antigen binding domain to its target and CDRs for binding a further target. The multivalent target-binding proteins are activated upon cleavage of the cleavable linkers. Also disclosed are pro immune modulating molecules comprising dual binding moieties comprising non-CDR loops and cleavable linkers, that prohibit the binding of a target binding domain to their targets (e.g., binding of an antibody to an immune modulatory target is masked by the dual binding moieties). The dual binding moieties further have specificity for a bulk serum protein or a dual binding moiety target (e.g., a tumor antigen, an immune modulatory protein).
    Type: Application
    Filed: September 20, 2019
    Publication date: November 18, 2021
    Inventors: Shuoyen Jack LIN, Holger WESCHE, Kathryn KWANT
  • Patent number: 11136403
    Abstract: Provided herein are B cell maturation agent (BCMA) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to BCMA. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such BCMA targeting trispecific proteins. Also disclosed are methods of using the disclosed BCMA targeting trispecific proteins in the prevention, and/or treatment diseases, conditions and disorders.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: October 5, 2021
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Holger Wesche, Bryan D. Lemon, Richard J. Austin
  • Publication number: 20210292421
    Abstract: Disclosed herein are binding moieties that comprise non-CDR loops for masking the binding of a binding molecule to its target and CDRs for binding bulk serum proteins. Conditionally active target binding proteins that contain the binding moieties are also provided. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are further provided.
    Type: Application
    Filed: May 14, 2019
    Publication date: September 23, 2021
    Inventors: Shuoyen Jack LIN, Richard J. AUSTIN, Bryan D. LEMON, Kathryn KWANT, Sony S. ROCHA, Holger WESCHE
  • Publication number: 20210284728
    Abstract: Disclosed herein is a dual binding moiety that comprises non-CDR loops for masking the binding of a domain, such as a target antigen binding domain to its target, by steric occlusion and specific masking, and CDRs for binding bulk serum proteins. Pharmaceutical compositions comprising the dual binding moiety disclosed herein and methods of using such compositions are further provided.
    Type: Application
    Filed: May 14, 2019
    Publication date: September 16, 2021
    Inventors: Shuoyen Jack LIN, Richard J. AUSTIN, Bryan D. LEMON, Holger WESCHE
  • Publication number: 20210269530
    Abstract: Disclosed herein is a conditionally active target binding protein that contains a first binding domain that binds to a bulk serum protein and sterically occludes binding of a second binding domain to its target. Pharmaceutical compositions comprising the conditionally active binding proteins disclosed herein and methods of using such compositions are further provided.
    Type: Application
    Filed: May 14, 2019
    Publication date: September 2, 2021
    Applicant: Harpoon Therapeutics, Inc.
    Inventors: Shuoyen Jack LIN, Richard J. AUSTIN, Bryan D. LEMON, Holger WESCHE
  • Publication number: 20210261671
    Abstract: Provided herein are FLT3 binding proteins, pharmaceutical compositions comprising such proteins or fragments thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such FLT3 binding proteins. Also disclosed are methods of using the disclosed FLT3 binding proteins in the prevention, and/or treatment of diseases, conditions and disorders.
    Type: Application
    Filed: February 19, 2021
    Publication date: August 26, 2021
    Inventors: Holger WESCHE, Richard J. AUSTIN
  • Patent number: 11085021
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: August 10, 2021
    Assignee: TCR2 THERAPEUTICS INC.
    Inventors: Patrick Baeuerle, Gregory Sieczkiewicz, Robert Hofmeister, Holger Wesche, Bryan D. Lemon, Richard J. Austin, Robert B. Dubridge
  • Publication number: 20210179735
    Abstract: Provided herein are trispecific antigen-binding proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to a target antigen. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such trispecific antigen-binding proteins. Also disclosed are methods of using the disclosed trispecific antigen-binding proteins in the prevention, and/or treatment diseases, conditions and disorders.
    Type: Application
    Filed: February 2, 2021
    Publication date: June 17, 2021
    Inventors: Patrick BAEUERLE, Luke EVNIN, Jeanmarie GUENOT, Vanitha RAMAKRISHNAN, Holger WESCHE
  • Publication number: 20210171649
    Abstract: Disclosed herein are B cell maturation antigen binding proteins with improved binding affinities and improved ability to mediate killing of cancer cells expressing B cell maturation antigen (BCMA). Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of treatment of a cancer or a metastasis thereof using such formulations are further provided.
    Type: Application
    Filed: January 15, 2021
    Publication date: June 10, 2021
    Inventors: Holger WESCHE, Bryan D. LEMON, Richard J. AUSTIN
  • Publication number: 20210100902
    Abstract: Disclosed are PSMA binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a PSMA binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed and methods of using such formulations are further provided.
    Type: Application
    Filed: September 23, 2020
    Publication date: April 8, 2021
    Inventors: Robert DUBRIDGE, Pui SETO, Patrick BAEUERLE, Jeanmarie GUENOT, Holger WESCHE, Bryan D. LEMON, Richard J. AUSTIN
  • Publication number: 20210095047
    Abstract: Provided herein are prostate specific membrane antigen (PSMA) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to PSMA. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such PSMA targeting trispecific proteins. Also disclosed are methods of using the disclosed PSMA targeting trispecific proteins in the prevention, and/or treatment diseases, conditions and disorders.
    Type: Application
    Filed: October 16, 2020
    Publication date: April 1, 2021
    Inventors: Patrick BAEUERLE, Jeanmarie GUENOT, Holger WESCHE, Robert B. DUBRIDGE, Bryan D. LEMON, Richard J. AUSTIN, Pui SETO
  • Patent number: 10954311
    Abstract: Provided herein are trispecific antigen-binding proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to a target antigen. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such trispecific antigen-binding proteins. Also disclosed are methods of using the disclosed trispecific antigen-binding proteins in the prevention, and/or treatment diseases, conditions and disorders.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: March 23, 2021
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Patrick Baeuerle, Luke Evnin, Jeanmarie Guenot, Vanitha Ramakrishnan, Holger Wesche
  • Patent number: 10927180
    Abstract: Disclosed herein are B cell maturation antigen binding proteins with improved binding affinities and improved ability to mediate killing of cancer cells expressing B cell maturation antigen (BCMA). Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of treatment of a cancer or a metastasis thereof using such formulations are further provided.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: February 23, 2021
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Holger Wesche, Bryan D. Lemon, Richard J. Austin
  • Publication number: 20210047439
    Abstract: Provided herein are DLL3 binding proteins and DLL3 targeting multispecific proteins (e.g., DLL3 targeting trispecific protein) comprising a domain binding to CD3, a half-life extension domain, and a domain binding to DLL3 (such as a DLL3 binding protein as provided herein). Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such DLL3 binding proteins, DLL3 targeting trispecific proteins. Also disclosed are methods of using the disclosed DLL3 binding proteins, DLL3 targeting trispecific proteins in the prevention, and/or treatment diseases, conditions and disorders.
    Type: Application
    Filed: August 21, 2020
    Publication date: February 18, 2021
    Inventors: Holger WESCHE, Richard J. AUSTIN